Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Biopsy proven stage I/II non-small cell lung cancer who are candidates for surgical resection~* Ambulatory and capable of all self-care but may be unable to carry out any work activities.~* Preoperative and postoperative high resolution CT scans done at NYPH-Weill Cornell medical center for purposes of volumetric measurements.~* Acceptable cardiac, breathing, kidney, liver, and bone marrow functions.~* 18 years and older.~* Women of child-bearing potential must be taking adequate contraceptive precautions prior to study entry and for the duration of study participation. A negative serum or urine pregnancy test is required within 7-10 days of Tarceva® administration. Men and premenopausal women of child bearing potential will follow an approved, medically accepted birth control regimen or agree to abstain from heterosexual intercourse while taking study drug and for 30 days following the last dose of study drug.~Exclusion Criteria:~* Cannot be on any other anti-cancer treatment during this study.~* Prior treatment with any EGFR inhibitor.~* Patients who had prior treatment with chemotherapy or radiation for this disease.~* Other active cancers.~* Tumors with a mixed histology of small cell and non-small cell carcinoma as well as patients with pulmonary carcinoid tumors.~* Gastro-intestinal abnormalities, including active peptic ulcer or inflammatory bowel disease.~* Hypersensitivity to compounds similar in chemical composition to Tarceva®.~* Active infection or serious underlying medical conditions which would impair protocol treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Erlotinib (Type: EXPERIMENTAL): Erlotinib 150mg/day for 3 weeks followed by surgical resection at week 4 then daily Tarceva® at 150 mg/day for 2 years for those patients who had a response rate of at least 50% tumor volume reduction and/or have EGFR-positive tumor tissue determined by IHC and/or FISH.

Based on this trial design, predict the completion outcome and termination type (if applicable).